The Proton Pump Inhibitors Market Is Estimated To Increase At A CAGR Of 4.5 Percent During The Forecast Period 2021-2026
Proton pump inhibitors are a class of drugs that limit gastric acid output in the stomach's linings. They inhibit an enzyme in the gastric system that actively transfers gastric acid in hydrogen–potassium adenosine triphosphate from parietal cells to the gastrointestinal lumen (proton pump). Gastroesophageal reflux disease (GERD), peptic ulcers, dyspepsia, gastritis, and other gastrointestinal problems are treated with proton pump inhibitors. The medications are used orally and come in the shape of capsules and pills. Because they have fewer adverse effects, proton pump inhibitors are among the most commonly prescribed drugs. The Proton Pump Inhibitors Market was worth USD 2,750 million in 2020, and it is expected to grow to USD 3,585 million in 2026, with a CAGR of almost 4.5 percent between 2021 and 2026. According to numerous studies, proton pump inhibitors have been linked to an increased risk of COVID-19 among individuals who use them. For example, in 2020, the American Journ